Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | PRNP | P04156 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15202096 | 0.85 | ALDH1A1 (0.50) | HTTNPC1RAB9ASRD5A2GSK3B | |
| SCHEMBL13461742 | 0.85 | HTT (0.47) | HTTNPC1RAB9ASRD5A2MAPK1 | |
| SCHEMBL15201466 | 0.84 | HRH3 (0.45) | HTTNPC1RAB9AHRH3SMN1; SMN2 | |
| SCHEMBL15201354 | 0.83 | LTA4H (0.49) | NPC1RAB9AHRH3MAPK1GSK3B | |
| SCHEMBL15648234 | 0.83 | CYP19A1 (0.42) | HTTNPC1RAB9AHPGDIDO1 | |
| SCHEMBL15201717 | 0.83 | LMNA (0.49) | HTTNPC1RAB9AHRH3MAPK1 | |
| SCHEMBL15646669 | 0.83 | MAPT (0.49) | HTTNPC1IDO1 | |
| SCHEMBL1045351 | 0.83 | MEN1 (0.46) | HTTSRD5A2MAPK1IDO1 | |
| SCHEMBL15201239 | 0.83 | SRD5A2 (0.46) | HTTNPC1RAB9ASRD5A2HPGD | |
| SCHEMBL5550351 | 0.83 | NAPRT (0.49) | HTTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2814814-B1 | IMIDAZOLYLKETONE DERIVATIVES ASD ALDOSTERONE SYNTHASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-05-08 | — | — | EP | claimed |
| US-9464058-B2 | Imidazolylketone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-10-11 | — | — | US | claimed |
| EP-3057950-B1 | PHENYL LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-02 | — | — | EP | disclosed |
| EP-3057951-B1 | METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2019-11-20 | — | — | EP | disclosed |
| US-10369146-B2 | Phenyl linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-06 | — | — | US | disclosed |
| US-10369146-B2 | Phenyl linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-06 | — | — | US | disclosed |
| EP-3057422-B1 | QUINOLINYL MODULATORS OF ROR(GAMMA)T | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-15 | — | — | EP | disclosed |
| EP-2814814-B1 | IMIDAZOLYLKETONE DERIVATIVES ASD ALDOSTERONE SYNTHASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-05-08 | — | — | EP | disclosed |
| EP-2814814-B1 | IMIDAZOLYLKETONE DERIVATIVES ASD ALDOSTERONE SYNTHASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-05-08 | — | — | EP | disclosed |
| US-10201546-B2 | Quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-12 | — | — | US | disclosed |
| US-10201546-B2 | Quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-12 | — | — | US | disclosed |
| WO-2005105783-A1 | DIASTEREOSELECTIVE SYNTHESIS PROCESS WITH 6-BROMO-4-(3-CHLOROPHENYL)-2-METHOXY-QUINOLINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-10 | — | — | WO | disclosed |
| US-6844357-B2 | Substituted quinolin-2-one derivatives useful as antiproliferative agents | PFIZER INC. (US) | 2005-01-18 | — | — | US | disclosed |
| US-20040067968-A1 | Farnesyl transferase inhibiting 4-heterocyclyl quinoline and quinazoline | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-08 | — | — | US | disclosed |
| EP-1351954-A1 | FARNESYL TRANSFERASE INHIBITING 4-HETEROCYCLYL-QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-15 | — | — | EP | disclosed |
| US-20030166675-A1 | Substituted quinolin-2-one derivatives useful as antiproliferative agents | PFIZER INC. | 2003-09-04 | — | — | US | disclosed |
| US-20020156113-A1 | Farnesyl transferase inhibitors; anticancer agents | LES LABORATOIRES SERVIER (FR) | 2002-10-24 | — | — | US | disclosed |
| WO-2002057258-A1 | CYCLO`D!AZEPANE DERIVATIVES WHICH ARE USED AS FARNESYLTRANSFERASE INHIBITORS AND METHOD FOR THE PREPARATION THEREOF | LES LABORATOIRES SERVIER (FR) | 2002-07-25 | — | — | WO | disclosed |
| EP-1225170-A2 | Cycloheptene compounds, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier S.A. (FR) | 2002-07-24 | — | — | EP | disclosed |
| WO-2002051834-A1 | FARNESYL TRANSFERASE INHIBITING 4-HETEROCYCLYL-QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10369146-B2 | Phenyl linked quinolinyl modulators of RORγt | RORC, RORB, RORA | HTT 1803/4885NPC1 2216/4885RAB9A 177/4885 |
| US-20020156113-A1 | Farnesyl transferase inhibitors; anticancer agents | COASY, FNTA, FNTB | HTT 4285/4885NPC1 30/4885RAB9A 755/4885 |
| US-20030166675-A1 | Substituted quinolin-2-one derivatives useful as antiproliferative agents | CCNA1, NRAS, CCNA2 | HTT 2745/4885NPC1 1182/4885RAB9A 399/4885 |
| US-20040067968-A1 | Farnesyl transferase inhibiting 4-heterocyclyl quinoline and quinazoline | FNTA, FNTB, ACAT2 | HTT 4526/4885NPC1 67/4885RAB9A 183/4885 |
| US-10201546-B2 | Quinolinyl modulators of RORγt | RORC, RORB, RORA | HTT 2241/4885NPC1 2137/4885RAB9A 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.